Latest AB Science News & Updates

See the latest news and media coverage for AB Science. We track all announcements, press releases, and industry mentions in real time, all in one place.

AB Science

Biopharmaceutical company developing small molecule drugs

ab-science.com

Last updated Today

Latest news about AB Science

In short: AB Science successfully completed a €14.2 million capital increase and narrowed its clinical focus to lead programs in ALS and AML.

Company announcements

July 10 AB Science

AB Science narrows clinical focus to two programs

It discontinues non-priority studies to concentrate on AB8939 for AML and masitinib for ALS.

July 8 AB Science

AB Science restructures its Board of Directors governance

The move appoints Stéphane Ledermann as Chairman and CEO to lead a new development phase.

June 17 AB Science

AB Science obtains US patent for masitinib in prostate cancer

The patent protects masitinib for treating metastatic castrate-resistant prostate cancer until 2042.

May 13 AB Science

AB Science reports 2025 annual financial results

The company reported its revenues for the year 2025 and provided an activity update.

Media coverage

August 17 The Manila Times

AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026

AB Science S.A. (the "Company" or "AB Science ," Euronext - FR0010557264 - AB) today announces the successful settlement and delivery of the securities issued...

August 11 Spot Bourse

AB Science price target: what are the consensus, volumes, and dilution worth?

Analyst consensus, share price, volumes, and dilution risk: decoding the AB Science price target to read volatility and identify the real catalysts...

August 10 Yahoo Finance

AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million

AB Science S.A. (the " Company " or " AB Science ", Euronext – FR0010557264 – AB) announces today the successful completion of capital increases...

June 17 The Manila Times

AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042

This new US patent adds to the IP coverage already granted in Europe (EP4175639). Counterpart patent applications have also been filed in other major international...

Never miss news about AB Science

Track AB Science and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.